Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study
Background Pancreatic cancer (PC) is often diagnosed at advanced stages, limiting surgical options. There is no standardized treatment for second-line or beyond therapies, necessitating alternative treatments. This study evaluates the efficacy and safety of anlotinib combined with chemotherapy in ad...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20565623.2025.2532327 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319282137104384 |
|---|---|
| author | Zhiyong Li Zhiming Wang Hexia Gan Feng Shen Lisha Cheng Xiuping Zhang |
| author_facet | Zhiyong Li Zhiming Wang Hexia Gan Feng Shen Lisha Cheng Xiuping Zhang |
| author_sort | Zhiyong Li |
| collection | DOAJ |
| description | Background Pancreatic cancer (PC) is often diagnosed at advanced stages, limiting surgical options. There is no standardized treatment for second-line or beyond therapies, necessitating alternative treatments. This study evaluates the efficacy and safety of anlotinib combined with chemotherapy in advanced PC patients receiving second-line or subsequent treatments.Methods A retrospective analysis of 68 advanced PC patients was conducted. Twenty-six patients treated with anlotinib and chemotherapy were compared to 42 controls who received chemotherapy only. Demographic data, efficacy, survival, and adverse reactions were analyzed.Results In the anlotinib group, the therapeutic responses were as follows: Complete Response: 0, Partial Response: 2 (7.7%), Stable Disease: 13 (50.0%), and Progressive Disease: 11 (42.3%), the Objective Remission Rate was 7.7%, and the Disease Control Rate was 57.7%. The median Progression-Free Survival was 4.5 months. The Overall Survival was significantly longer in the anlotinib group compared to controls. Common adverse reactions included fatigue, bone marrow suppression, and hypertension, mostly grade 1–3. The potential toxicity and cumulative toxicity of long-term use is hand-foot syndrome, hypothyroidism and hypertension.Conclusion The data generated suggest that anlotinib combined with chemotherapy may be an effective and tolerable option for second-line and subsequent treatment of advanced PC. |
| format | Article |
| id | doaj-art-7d209d702b08408b9d77d4ddaf80a626 |
| institution | Kabale University |
| issn | 2056-5623 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-7d209d702b08408b9d77d4ddaf80a6262025-08-20T03:50:32ZengTaylor & Francis GroupFuture Science OA2056-56232025-12-0111110.1080/20565623.2025.2532327Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective studyZhiyong Li0Zhiming Wang1Hexia Gan2Feng Shen3Lisha Cheng4Xiuping Zhang5Department of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, ChinaBackground Pancreatic cancer (PC) is often diagnosed at advanced stages, limiting surgical options. There is no standardized treatment for second-line or beyond therapies, necessitating alternative treatments. This study evaluates the efficacy and safety of anlotinib combined with chemotherapy in advanced PC patients receiving second-line or subsequent treatments.Methods A retrospective analysis of 68 advanced PC patients was conducted. Twenty-six patients treated with anlotinib and chemotherapy were compared to 42 controls who received chemotherapy only. Demographic data, efficacy, survival, and adverse reactions were analyzed.Results In the anlotinib group, the therapeutic responses were as follows: Complete Response: 0, Partial Response: 2 (7.7%), Stable Disease: 13 (50.0%), and Progressive Disease: 11 (42.3%), the Objective Remission Rate was 7.7%, and the Disease Control Rate was 57.7%. The median Progression-Free Survival was 4.5 months. The Overall Survival was significantly longer in the anlotinib group compared to controls. Common adverse reactions included fatigue, bone marrow suppression, and hypertension, mostly grade 1–3. The potential toxicity and cumulative toxicity of long-term use is hand-foot syndrome, hypothyroidism and hypertension.Conclusion The data generated suggest that anlotinib combined with chemotherapy may be an effective and tolerable option for second-line and subsequent treatment of advanced PC.https://www.tandfonline.com/doi/10.1080/20565623.2025.2532327Advanced pancreatic canceranlotinibchemotherapysecond-line treatmentprogression-free survivaladverse reactions |
| spellingShingle | Zhiyong Li Zhiming Wang Hexia Gan Feng Shen Lisha Cheng Xiuping Zhang Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study Future Science OA Advanced pancreatic cancer anlotinib chemotherapy second-line treatment progression-free survival adverse reactions |
| title | Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study |
| title_full | Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study |
| title_fullStr | Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study |
| title_full_unstemmed | Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study |
| title_short | Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study |
| title_sort | real world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer a retrospective study |
| topic | Advanced pancreatic cancer anlotinib chemotherapy second-line treatment progression-free survival adverse reactions |
| url | https://www.tandfonline.com/doi/10.1080/20565623.2025.2532327 |
| work_keys_str_mv | AT zhiyongli realworldefficacyandsafetyofanlotinibcombinedwithchemotherapyforadvancedpancreaticcanceraretrospectivestudy AT zhimingwang realworldefficacyandsafetyofanlotinibcombinedwithchemotherapyforadvancedpancreaticcanceraretrospectivestudy AT hexiagan realworldefficacyandsafetyofanlotinibcombinedwithchemotherapyforadvancedpancreaticcanceraretrospectivestudy AT fengshen realworldefficacyandsafetyofanlotinibcombinedwithchemotherapyforadvancedpancreaticcanceraretrospectivestudy AT lishacheng realworldefficacyandsafetyofanlotinibcombinedwithchemotherapyforadvancedpancreaticcanceraretrospectivestudy AT xiupingzhang realworldefficacyandsafetyofanlotinibcombinedwithchemotherapyforadvancedpancreaticcanceraretrospectivestudy |